Notably, emergence of the FGFR3::TACC3 fusion as a resistance mechanism in TKI-treated EGFR-mutated lung adenocarcinoma was associated with a tendency towards SCC-like transdifferentiation [9]. The gene discussed is FGFR3; the disease is lung adenocarcinoma.